To acquire 23andMe’s Personal Genome Service, Total Health and Research Services business lines, and its Biobank and ...

Meacham argues Regeneron's Eylea franchise and melanoma pipeline optionality leave it well-positioned, raising his price target to $700 from $600 after a roughly 55% stock pullback since last year ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market Jury awarded ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more. From STAT’s Andrew Joseph: Lars Fruergaard ...

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals REGN, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Yancopoulos Innovator Award at the 75 th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest pre-college science and engineering competition. The award is named ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...